Log in to search using one of your social media accounts:

 

Single-Pill HIV Regimen Scores in New Patients Single-Pill HIV Regimen Scores in New Patients
A new single-tablet regimen with boosted darunavir and tenofovir alafenamide works in virally suppressed HIV patients, AMBER trial results confirm, but when should it be tried in the treatment na ï ve?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Tenofovir Prodrug Goes Head to Head Against Abacavir in HIV Tenofovir Prodrug Goes Head to Head Against Abacavir in HIV
A lot has been made of the better renal and bone safety with the tenofovir alafenamide prodrug than with the older formulation, but is it better than other antiretrovirals?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news

Single-tablet Switch Option Effective in Virologically Suppressed HIV Single-tablet Switch Option Effective in Virologically Suppressed HIV
A new single-tablet regimen (STR) that includes the protease inhibitor (PI) darunavir, cobicistat, emtricitabine, and tenofovir alafenamide maintains viral suppression in adults infected with HIV-1, according to results from the EMERALD phase 3 noninferiority trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 20, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Janssen seeks approval for investigational regimen that aims to combine efficacy, durability, and the high genetic barrier to resistance of darunavir with the renal and bone safety profile of emtricitabine/tenofovir alafenamide in a once daily pill (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 19, 2017 Category: Pharmaceuticals Source Type: news

HIV prevention drug could save NHS £1 billion over 80 years
Conclusion Evidence to support the use of Prep is building. Studies have shown that it is very effective at reducing the chances of becoming infected with HIV, for men at risk of infection through unprotected sex with men. The question is more about the cost of treatment – and who should fund it – than whether it works. NHS England previously went to court to say that it should not be responsible for funding Prep, as it is a preventive treatment, and therefore should come under health promotion budgets held by local authorities. The High Court ruled that the NHS was able to fund the drug. NHS England has since ...
Source: NHS News Feed - October 19, 2017 Category: Consumer Health News Tags: Medication Source Type: news

Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens
EMERALD 48-week safety and efficacy results published in The Lancet HIV and to be presented at IDWeek (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 6, 2017 Category: Pharmaceuticals Source Type: news

Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1 Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1
A 1,200-mg, once-daily regimen of raltegravir, in combination with tenofovir disoproxil fumarate and emtricitabine, is effective in patients with previously untreated HIV-1 infection, according to results from the ONCEMRK trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 26, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

New Guidelines Issued on HIV Treatment During Pregnancy (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Tenofovir-emtricitabine should not be a first treatment choice for women with HIV who are pregnant, according to new patient-centered … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 12, 2017 Category: Primary Care Source Type: news

Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women
Maraviroc-containing regimens appear to be safe and well tolerated, compared with tenofovir-emtricitabine (TDF-FTC), for preventing HIV infection in women, according to results from a phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Aurobindo Pharma gets USFDA nod for anti-HIV drug
Aurobindo Pharma has received tentative approval from the USFDA for dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, used for the treatment of HIV, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 21, 2017 Category: Pharmaceuticals Source Type: news

Mylan rolls out HIV treatment medicine in Canada
Mylan launched three generic medications to treat HIV in Canada. The pharmaceutical company, which is based in the Netherlands but run out of its corporate offices in Canonsburg, said it had received Health Canada approval for these generic drugs: emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg, a generic alternative to Truvada efavirenz/emtricitabin e/tenofovir disoproxil fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla tenofovir disoproxil 300 mg, a generic alternative… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 10, 2017 Category: American Health Authors: Paul J. Gough Source Type: news

Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1 HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan Pharmaceuticals ULC, a subsid... Biopharmaceuticals, Generics, Product Launch Mylan, Truvada, Atripla, Viread (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 10, 2017 Category: Pharmaceuticals Source Type: news

Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 10, 2017-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company ’s New Drug Application (NDA) for an... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 10, 2017 Category: Drugs & Pharmacology Source Type: news

Mylan launches new HIV treatment in India
Mylan NV said it is the first company to offer an innovative, reduced-dose HIV treatment in India. Mylan (Nasdaq:MYL) subsidiary Mylan Pharmaceuticals Private Limited has received marketing authorization from the Drug Controller General of India for its antiretroviral drug Avonza. The fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets is recommen ded by the World Health Organization as an alternative first-line regimen for people being treated for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 9, 2017 Category: Pharmaceuticals Authors: Patty Tascarella Source Type: news

Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz
Exposure of infants, from conception, to the antiretroviral combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TFC-FTC-EFV) is associated with a lower risk of adverse birth outcomes, compared with exposure to other antiretroviral regimens, according to data from Botswana.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Bone Risk with Tenofovir: How to Handle? (CME/CE)
(MedPage Today) -- Studies examine role of common HIV drug (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 28, 2017 Category: Primary Care Source Type: news

Janssen Receives Positive CHMP Opinion for SYMTUZA ™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
- Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet (Source: Johnson and Johnson)
Source: Johnson and Johnson - July 21, 2017 Category: Pharmaceuticals Source Type: news

Tenofovir to Prevent Mother-to-child Transmission of HBV Tenofovir to Prevent Mother-to-child Transmission of HBV
Is tenofovir safe and tolerable for both the mother and fetus when administered to pregnant women with chronic HBV infection?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

How Common Are STIs?
Discussion Of the 30 different microbes which can be transmitted by sexual contact, 8 have the greatest incidence of transmitting disease. Four are curable (Chlamydia, Gonorrhea, Syphilis and Trichomoniasis) and 4 are incurable at present (Hepatitis B, Herpes simplex virus (HSV), Human immunodeficiency virus (HIV) and Human papillomavirus (HPV)). Sexually transmitted infections (STIs) are important as they can cause: Increased rates of acquisition of other STIs (ie HSV and syphilis increase the rate of HIV infection acquisition) Pelvic inflammatory disease and infertility Stillbirth and neonatal death Neonatal morbidity i...
Source: PediatricEducation.org - July 17, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

HCC Drops Beyond Five Years of Entecavir/Tenofovir Tx for Hep B
Older age, lower platelets at baseline and year five, liver stiffness ≥ 12 kPa linked to HCC development (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 21, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Oncology, Pharmacy, Journal, Source Type: news

Efficacy and Safety After Switching From TDF to TAF in HIV Efficacy and Safety After Switching From TDF to TAF in HIV
What benefits might tenofovir alafenamide offer virologically suppressed HIV patients over tenofovir disoproxil fumarate?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2017 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 12, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 12, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Generic Truvada in US FDA Approves First Generic Truvada in US
Generic versions of emtricitabine/tenofovir disoproxil, which can both treat and prevent HIV infections, are already available in other countries.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2017 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

Health Highlights: June 9, 2017
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Generic Version of HIV Drug Truvada Approved by FDA The first generic version of the HIV drug Truvada (emtricitabine and tenofovir disoproxil... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 9, 2017 Category: General Medicine Source Type: news

Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
This study provides evidence linking vaginal bacteria to microbicide efficacy through tenofovir depletion via bacterial metabolism. (Source: ScienceNOW)
Source: ScienceNOW - June 1, 2017 Category: Science Authors: Klatt, N. R., Cheu, R., Birse, K., Zevin, A. S., Perner, M., Noël-Romas, L., Grobler, A., Westmacott, G., Xie, I. Y., Butler, J., Mansoor, L., McKinnon, L. R., Passmore, J.-A. S., Abdool Karim, Q., Abdool Karim, S. S., Burgener, A. D. Tags: Medicine, Diseases r-articles Source Type: news

Gilead reports positive data from four Phase III combination trials for HIV-1
US-based biopharmaceutical firm Gilead Sciences has reported positive results from four Phase III clinical trials investigating the combination of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) to treat patients with HIV-1. (Source: Drug Development Technology)
Source: Drug Development Technology - May 30, 2017 Category: Pharmaceuticals Source Type: news

Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2017 Category: Drugs & Pharmacology Source Type: news

New Tenofovir for Hep B Improves Bone and Kidney Safety (CME/CE)
(MedPage Today) -- Formulation now recommended in updated HBV treatment guidelines (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 24, 2017 Category: Gastroenterology Source Type: news

Viread (Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 24, 2017 Category: Drugs & Pharmacology Source Type: news

Atripla (Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 24, 2017 Category: Drugs & Pharmacology Source Type: news

Odefsey (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Fixed-dose Combination Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 20, 2017 Category: Drugs & Pharmacology Source Type: news

NHS' anti-HIV drug PrEP approved in Scotland, UK
The Scottish Medicines Consortium (SMC), UK, has approved the supply of Emtricitabine / tenofovir disoproxil (Truvada) by the National Health Service (NHS) to prevent HIV in the nation. (Source: Drug Development Technology)
Source: Drug Development Technology - April 10, 2017 Category: Pharmaceuticals Source Type: news

Vemlidy Tablets (Tenofovir Alafenamide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 10, 2017 Category: Drugs & Pharmacology Source Type: news

New Tenofovir Prodrug Is Noninferior to Currently Used Prodrug New Tenofovir Prodrug Is Noninferior to Currently Used Prodrug
Antiretroviral (ART) combinations containing the recently approved tenofovir alafenamide prodrug offer similar effectiveness and tolerability to those of combinations containing tenofovir disoproxil fumarate, according to two noninferiority trials.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 10, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Stribild (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir DF) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 10, 2017 Category: Drugs & Pharmacology Source Type: news

Tenofovir Disoproxil Fumarate Safety for Women and Infants Tenofovir Disoproxil Fumarate Safety for Women and Infants
What does available safety data tell us about preexposure prophylaxis with tenofovir disoproxil fumarate during pregnancy and lactation?AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2017 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Europe Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV Europe Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV
The efficacy of once-daily Vemlidy is similar to that of tenofovir disoproxil (Viread) with fewer bone and renal side effects, the company says.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 14, 2017 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

CDC guidelines for HIV prevention regimen may not go far enough, study suggests
A new study from the UCLA Fielding School of Public Health suggests modifying federal health guidelines related to the use of pre-exposure prophylaxis to prevent HIV transmission because current standards could miss some people who should be on it.Pre-exposure prophylaxis, or PrEP, is a measure that has proven to be highly effective in preventing HIV transmission during unprotected sex. While not entirely foolproof, studies have shown taking daily doses of tenofovir disoproxil-emtricitabine, or Truvada, is 92 percent effective in preventing HIV infection when taken correctly and consistently.Since 2012, the U.S. Centers fo...
Source: UCLA Newsroom: Health Sciences - January 7, 2017 Category: Universities & Medical Training Source Type: news

ContraVir reports positive Phase IIa trial data of tenofovir exalidex to treat Hepatitis B infection
US-based biopharmaceutical company ContraVir has reported positive data from its ongoing Phase IIa trial of tenofovir exalidex (TXL) to treat Hepatitis B infection. (Source: Drug Development Technology)
Source: Drug Development Technology - December 21, 2016 Category: Pharmaceuticals Source Type: news

Genvoya (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 20, 2016 Category: Drugs & Pharmacology Source Type: news

HIV prevention trials network launches HPTN 083
(FHI360) The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). If found to be safe and effective for HIV pre-exposure prophylaxis, also known as PrEP, injectable CAB may be easier for some people to adhere to than daily oral TDF/FTC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2016 Category: Global & Universal Source Type: news

The Success Of HIV Treatment Is Increasing The Risk Of Drug-Resistance
Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa.  Like tuberculosis and other diseases, drug resistant HIV strains emerge in part because a person doesn’t take the proper dose of drugs at the right time every day. In poor regions like...
Source: Science - The Huffington Post - December 6, 2016 Category: Science Source Type: news

The Success Of HIV Treatment Is Increasing The Risk Of Drug-Resistance
Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing new trend: The rise of drug-resistant HIV strains, especially in countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa.  Like tuberculosis and other diseases, drug resistant HIV strains emerge in part because a person doesn’t take the proper dose of drugs at the right time every day. In poor regions like...
Source: Healthy Living - The Huffington Post - December 6, 2016 Category: Consumer Health News Source Type: news

Tanzania: Muhimbili National Hospital Plans Free Hepatitis Treatment
[Daily News] Muhimbili National Hospital (MNH) plans to establish a diagnosis of hepatitis B virus and offer free treatment with Tenofovir medication to patients for five years effective next month. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - November 29, 2016 Category: African Health Source Type: news

Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection
Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - November 24, 2016 Category: Pharmaceuticals Source Type: news

Vemlidy Tablets (Tenofovir Alafenamide) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 23, 2016 Category: Drugs & Pharmacology Source Type: news

CHMP Backs Tenofovir Alafenamide (Vemlidy) for Chronic Hep B CHMP Backs Tenofovir Alafenamide (Vemlidy) for Chronic Hep B
Vemlidy has efficacy similar to that of tenofovir disoproxil (Viread), with fewer bone and renal side effects.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 11, 2016 Category: Drugs & Pharmacology Tags: Infectious Diseases News Alert Source Type: news

FDA Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV FDA Clears Tenofovir Alafenamide (Vemlidy) for Chronic HBV
Once-daily Vemlidy has similar efficacy to tenofovir disoproxil (Viread) with fewer bone and renal side effects, the company says.FDA Approvals (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - November 11, 2016 Category: Respiratory Medicine Tags: Gastroenterology News Source Type: news

Novel Tenofovir Drug OK'd for Hepatitis B
(MedPage Today) -- Vemlidy approved for chronic HBV infection with compensated liver disease (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 10, 2016 Category: American Health Source Type: news

FDA Approves Gilead ’s Vemlidy (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy ® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 10, 2016 Category: Drugs & Pharmacology Source Type: news